Literature DB >> 3360051

Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.

F A Pieters1, F Woonink, J Zuidema.   

Abstract

In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated. Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23). Correspondingly, the plasma dapsone 24 h after the last dose had fallen significantly from 2.63 to 2.02 mg/l. Clofazimine did not cause change in the pharmacokinetics of dapsone. It was concluded that, although rifampicin had a considerable influence on the pharmacokinetics of dapsone, there is no reason to adjust the dose of dapsone during multidrug therapy of leprosy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3360051     DOI: 10.1007/bf01061421

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Rifampin-induced methadone withdrawal.

Authors:  M J Kreek; J W Garfield; C L Gutjahr; L M Giusti
Journal:  N Engl J Med       Date:  1976-05-13       Impact factor: 91.245

2.  The pharmacokinetics of dapsone after oral administration to healthy volunteers.

Authors:  F A Pieters; J Zuidema
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

3.  Interaction of sodium warfarin and rifampin. Studies in man.

Authors:  R A O'Reilly
Journal:  Ann Intern Med       Date:  1974-09       Impact factor: 25.391

4.  Dapsone metabolism in patients with dapsone-resistant leprosy.

Authors:  R H Gelber; R J Rees
Journal:  Am J Trop Med Hyg       Date:  1975-11       Impact factor: 2.345

5.  The absolute oral bioavailability of dapsone in dogs and humans.

Authors:  F A Pieters; J Zuidema
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-07

6.  A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone.

Authors:  F A Pieters; F Woonink; J Zuidema
Journal:  Int J Lepr Other Mycobact Dis       Date:  1988-03

7.  Sex differences in the absorption of dapsone after intramuscular injection.

Authors:  E S Modderman; F W Merkus; J Zuidema; H W Hilbers; T Warndorff
Journal:  Int J Lepr Other Mycobact Dis       Date:  1983-09

8.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

9.  Spot test for detection of dapsone in urine: an assessment of its validity and interpretation in monitoring dapsone self-administration.

Authors:  H Huikeshoven; M G Madarang
Journal:  Int J Lepr Other Mycobact Dis       Date:  1986-03

10.  Application of spectrophotofluorometric procedures to some problems in Mycobacterium leprae infections in mice and man treated with dapsone (DDS), diacetyl-DDS (DADDS), and di-formyl-DDS (DFD).

Authors:  T Ozawa; C C Shepard; A B Karat
Journal:  Am J Trop Med Hyg       Date:  1971-03       Impact factor: 2.345

View more
  4 in total

Review 1.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.

Authors:  A Sowunmi; T J Rashid; O O Akinyinka; A G Renwick
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 3.  Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes.

Authors:  Bernard J Brabin; Teunis A Eggelte; Monica Parise; Francine Verhoeff
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 4.  Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.

Authors:  Luka Verrest; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.